The G protein‐coupled receptor GPR 89 A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells
The FEBS Journal · 2025
DOI: 10.1111/febs.70099 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Hale Guler Kara und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Ege University School of Medicine, Izmir, Turkey. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Carcinoma, Non-Small-Cell Lung, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Türkiye Bilimsel ve Teknolojik Araştırma Kurumu, Ege University Research Foundation.
Abstract (Originalsprache)
Lung cancer is the most frequently diagnosed cancer type worldwide and is characterised by its high metastatic potential. Standard therapy for nonsmall cell lung cancer (NSCLC) cases includes chemotherapy with the platinum‐based chemotherapeutic agent cisplatin. Although lung cancer cases respond well to cisplatin at the beginning of treatment, ~ 60% develop chemotherapy resistance during this process. In this study, a genome‐wide CRISPR‐Cas9‐based genetic screening approach was employed to identify genes that cisplatin‐resistant NSCLC Calu1 cells are more addicted to than sensitive cells. Cisplatin‐resistant Calu1 cells were generated by the dose escalation method, and genome‐wide CRISPR‐Cas9‐based genetic screening was performed with the Brunello CRISPR knockout library. Bioinformatics analyses of the obtained next‐generation sequencing data revealed 63 potential candidate genes responsible for cisplatin resistance, including G protein‐coupled receptor 89A ( GPR89A ), Poly(U) binding splicing factor 60 ( PUF60 ), NBAS subunit of NRZ tethering complex ( NBAS ) and GrpE like 1 , mitochondrial ( GRPEL1 ). The GPR89A protein is located in the Golgi cisterna and Golgi‐associated vesicle membrane, enables voltage‐gated anion channel activity, and is involved in intracellular pH reduction. Functional studies carried out with GPR89A ‐knockout cisplatin‐resistant Calu1 cells resulted in cell cycle arrest in the G2/M phase and increased polyploidy, and also prevented colony formation and cell migration. Cisplatin treatment, on the other hand, resulted in increased cell death by apoptosis upon cell cycle arrest in the S phase. In conclusion, this is the first study that identified GPR89A as a potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biology, Ege University School of Medicine, Izmir, Turkey.
- Department of Medical Biology, Harran University School of Medicine, Sanliurfa, Turkey.
- Department of Medical Biology, Bandirma Onyedi Eylul University School of Medicine, Balikesir, Turkey.
- Izmir Biomedicine and Genome Center, Turkey.
- Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey.
- Department of Bioengineering, Ege University School of Engineering, Izmir, Turkey.
ORCID-Profile: Hale Guler Kara, Serif Senturk
Förderung
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
- Ege University Research Foundation
Zitieren
APA
Guler Kara, H., Dogan, E., Bozok, V., Aktan, C., Cakiroglu, E., Eroglu, Z., Aygunes Jafari, D., Korkmaz, K. S., Senturk, S., & Kosova, B. (2025). The G protein‐coupled receptor GPR 89 A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells. The FEBS Journal. https://doi.org/10.1111/febs.70099
Vancouver
Guler Kara H, Dogan E, Bozok V, Aktan C, Cakiroglu E, Eroglu Z, et al. The G protein‐coupled receptor GPR 89 A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells. The FEBS Journal. 2025. doi:10.1111/febs.70099
BibTeX
@article{GulerKara2025,
author = {Guler Kara, Hale and Dogan, Eda and Bozok, Vildan and Aktan, Cagdas and Cakiroglu, Ece and Eroglu, Zuhal and Aygunes Jafari, Duygu and Korkmaz, Kemal Sami and Senturk, Serif and Kosova, Buket},
title = {The G protein‐coupled receptor GPR 89 A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells},
journal = {The FEBS Journal},
year = {2025},
doi = {10.1111/febs.70099}
}
EUVIMED